Angola vs El Salvador: Average cost of multi drug-resistant tuberculosis treatment
Angola
537 constant 2022 US$
in 2023
El Salvador
574 constant 2022 US$
in 2024
Angola rank
76th
El Salvador rank
73rd
Average cost of multi drug-resistant tuberculosis treatment over time
- Angola
- El Salvador
How they compare
El Salvador currently reports 574 constant 2022 US$ against 537 constant 2022 US$ in Angola, a difference of 37 constant 2022 US$.
That makes El Salvador's figure about 1.1 times Angola's.
The two have swapped places 1 time across 7 shared years of data; in 2017 it was Angola ahead.
Angola ranks 76th and El Salvador ranks 73rd of 92 countries.
Across the 2 decades both report, Angola averaged higher in 1 and El Salvador in 1.
Head to head by decade
| Decade | Angola | El Salvador | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,284 constant 2022 US$ | 1,590 constant 2022 US$ | 693.67 constant 2022 US$ | Angola |
| 2020s | 1,917 constant 2022 US$ | 3,867 constant 2022 US$ | 1,950 constant 2022 US$ | El Salvador |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Angola or El Salvador?
- El Salvador, at 574 constant 2022 US$ against 537 constant 2022 US$ in Angola as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Angola and El Salvador?
- 37 constant 2022 US$, with El Salvador ahead.
- How many years of comparable data are there for Angola and El Salvador?
- 7 years are reported by both, from 2017 to 2023.
- How do Angola and El Salvador rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Angola ranks 76th and El Salvador ranks 73rd of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.